Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangamo BioSciences has entered into a second research and license agreement with Genentech, expanding on the original agreement to include additional targets for potential improvement of production cell lines using Sangamo's proprietary zinc finger DNA-binding protein nuclease or ZFN technology.
Subscribe to our email newsletter
ZFNs are engineered forms of zinc finger DNA-binding proteins that also contain a nuclease component, which can induce modification of a target gene of interest
Edward Lanphier, president and CEO of Sangamo, said: “Under this second non-exclusive, research and commercial license agreement, Sangamo will design and engineer additional ZFNs that target genes identified by Genentech to potentially improve protein pharmaceutical production in mammalian cells. This further agreement strengthens our belief that there is a growing appreciation of the value of our technology which provides a rapid, reliable and highly specific method to efficiently alter genes in eukaryotic cells.”